The lancet. Gastroenterology & hepatology
-
Lancet Gastroenterol Hepatol · Jun 2021
Randomized Controlled Trial Multicenter StudyDiscontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Anti-tumour necrosis factor (TNF) agents are the mainstay of long-term treatment for refractory ulcerative colitis. However, long-term use of anti-TNF therapy might lead to an increased risk of malignancy or infection. To date, no randomised controlled trial has evaluated whether anti-TNF agents can be safely discontinued in patients with ulcerative colitis in remission. We therefore aimed to compare outcomes in these patients who continued infliximab with those who discontinued infliximab. ⋯ For the Japanese translation of the abstract see Supplementary Materials section.